A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies
Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported
responses in lymphoid malignancies but larger studies are needed.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants with Overall Response
Overall responses (OR) of participants with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin defined as Complete Response (CR) and Partial Response (PR).
Baseline and approximately every 3 weeks thereafter
Razelle Kurzrock, MD
United States: Food and Drug Administration
|M. D. Anderson Cancer Center||Houston, Texas 77030|